2 results match your criteria: "Tumor Center Rhein-Main[Affiliation]"
Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studies.
Eur J Cancer
November 2015
University Hospital Frankfurt, Tumor Center Rhein-Main, Frankfurt/Main, Germany.
Aim: To assess the efficacy and safety of everolimus in patients with metastatic renal cell carcinoma (mRCC) who failed one or two anti-VEGF therapies.
Patients And Methods: Data from four prospective, non-interventional studies conducted in Germany, France, Greece and Austria were pooled for this analysis. Patients with mRCC of any histology (clear cell or non-clear cell) were included.
Intraperitoneal chemotherapy with mitoxantrone in malignant ascites.
Surg Oncol Clin N Am
July 2003
Department of Visceral and Oncologic Surgery, Asklepios Paulinen Klinik and Asklepios, Tumor Center Rhein-Main (ATC), Geisenheimer Str. 10, D 65197 Wiesbaden, Germany.
A retrospective analysis of intraperitoneal mitoxantrone instillation therapy for malignant ascites in advanced breast and gynecologic pelvic cancers was performed to confirm the efficacy and safety of this therapy. Several smaller phase II trials had suggested good palliative effects. In 143 patients (37 breast cancer and 106 gynecologic cancers), 257 instillations were registered.
View Article and Find Full Text PDF